Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 04, 2025 07:30 ET | Source: TG Therapeutics, Inc.

TG Therapeutics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

NEW YORK, Sept. 04, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will participate in the...
September 03, 2025 07:30 ET | Source: TG Therapeutics, Inc.

TG Therapeutics Announces Completion of Existing Share Repurchase Program and Authorization of New $100 Million Program

NEW YORK, Sept. 03, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that it has completed its previously authorized $100 million share repurchase program, which was...
August 28, 2025 08:00 ET | Source: TG Therapeutics, Inc.

TG Therapeutics to Participate in the Cantor Global Healthcare Conference

NEW YORK, Aug. 28, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will participate in the...
August 04, 2025 07:00 ET | Source: TG Therapeutics, Inc.

TG Therapeutics Reports Second Quarter 2025 Financial Results and Raises BRIUMVI Revenue Guidance

Second quarter 2025 total revenue of $141.1 million, including BRIUMVI U.S. net revenue of $138.8 million Raises full year 2025 BRIUMVI U.S. net revenue target to approximately $570 - $575 million ...
July 30, 2025 07:30 ET | Source: TG Therapeutics, Inc.

TG Therapeutics to Host Conference Call on Second Quarter 2025 Financial Results and Business Update

NEW YORK, July 30, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held, Monday, August 4, 2025, at 8:30 AM ET to discuss results for...
June 06, 2025 07:30 ET | Source: TG Therapeutics, Inc.

TG Therapeutics to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

NEW YORK, June 06, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will participate in the...
June 02, 2025 08:00 ET | Source: TG Therapeutics, Inc.

TG Therapeutics to Participate in the Jefferies Global Healthcare Conference

NEW YORK, June 02, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will participate in the...
May 30, 2025 07:30 ET | Source: TG Therapeutics, Inc.

TG Therapeutics Announces Data Presentations for BRIUMVI in Multiple Sclerosis at the 2025 Consortium of Multiple Sclerosis Centers Annual Meeting

NEW YORK, May 30, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the presentations of data highlighting BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of...
May 27, 2025 07:30 ET | Source: TG Therapeutics, Inc.

TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® in Multiple Sclerosis at the 2025 Consortium of Multiple Sclerosis Centers Annual Meeting

NEW YORK, May 27, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the upcoming schedule of presentations highlighting BRIUMVI® (ublituximab-xiiy) data in patients with...
May 05, 2025 07:00 ET | Source: TG Therapeutics, Inc.

TG Therapeutics Reports First Quarter 2025 Financial Results and Raises BRIUMVI Full Year Revenue Guidance

First quarter 2025 BRIUMVI U.S. net revenue of $119.7 million Raises full year 2025 global net revenue target to approximately $575 million and raises full year BRIUMVI U.S. net revenue target to...